Robert Malenka Sells 6,612 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,612 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $18.11, for a total transaction of $119,743.32. Following the completion of the sale, the director owned 365,273 shares in the company, valued at $6,615,094.03. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Maplight Therapeutics Trading Down 4.8%

Shares of MPLT stock opened at $17.69 on Friday. The firm has a market capitalization of $802.60 million and a P/E ratio of -0.48. The stock’s fifty day moving average price is $17.62. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Morgan Stanley started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price on the stock. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Stifel Nicolaus started coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Weiss Ratings began coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.